Related by context. All words. (Click for frequent words.) 62 Docket # 60 Fitch Rates CWALT 60 C# [002] 60 G# [006] 60 WL # SDNY [001] 60 WL # [002] 59 NDNY 59 Bankr. EDNC 58 PT Ctfs Series 58 G# [003] 58 § #-#-# b [003] 58 NIH Publication 58 Repl. 58 SDNY Mar. 58 EDNY 57 #B# [009] 57 App'x 57 Misc 3d 57 Suppl 57 H# [005] 57 SECURITIES LITIGATION 57 J Am Soc 56 WDNY 56 TVID 56 App. Div 56 J Clin Oncol 56 ED Tex. 56 lipoprotein associated phospholipase 56 CD# [004] 56 D# [004] 56 SUMMARY JUDGMENT 56 LEXIS 56 :5 55 Dkt. 55 NW ¼ 55 SUMMARY NOTICE OF 55 Ann Oncol 55 Docket No. 55 No. #AP 55 #.#MM Mtge PT Ctfs 55 Cal. Ct 55 #AP# [002] 55 FASEB J. 55 ND Tex. 55 See ARS § 55 #A# #A# 55 Docket Number 55 deoxy 55 Suppl. 55 #:#-# [002] 55 Del. Ch 55 Slip Op 55 Dkt 55 Eur Urol 54 Pegylated Liposomal Doxorubicin 54 Cal. App 54 #:#-# [020] 54 Nephrol 54 LEXIS # [001] 54 #F [005] 54 #:#-# [025] 54 Exh 54 PT Ctfs 54 CV# [004] 54 Dkt. # 54 Dkt. No. 54 § #E 54 Bankr. D. Mass. 54 Cancer Res 54 #:# CV# 54 #P [004] 54 HE1 54 Obes Res 54 abstr 54 SD Tex. 54 S1 S# [001] 54 Coleshill Utd 54 Docket Nos. 54 #-#-# COPYRIGHT 54 Reproduced Record RR 54 Asset Backed Certificates 54 Resp't 54 Rzeczpospolita pp. A1 54 PT S# 54 T# R# 54 Doc. No. 54 Ctfs 54 Bankr 54 LSA RS #:# [002] 54 #-# #-# [013] 54 #S #S [002] 54 ASSIGNMENT OF ERROR 54 NC1 54 suppl 54 PROTEGE 54 suppl #S 54 Deadlinepix 54 Abstract Number 54 Supplemental Figure 54 CWALT 54 J Clin Psychiatry 54 Br J Psychiatry 54 App.R. 54 Def. s 54 Cell Physiol 54 Supp. 53 DOI #.#/S#-# 53 CV# [001] 53 Mol Cell 53 #a #a [003] 53 S# S# [001] 53 #U [005] 53 #S #S [001] 53 J Rheumatol 53 Nucleic Acids Res 53 #a #a [001] 53 mso ansi language 53 selective antagonist 53 Judgments § 53 Obstet Gynecol 53 Dent Res 53 #CB 53 DEER Antlered 53 Am J Epidemiol 53 Fed. 53 #S #S [003] 53 Endocrinol Metab 53 Ala. Civ 53 HE2 53 #C [005] 53 EN1 53 Thromb Haemost 53 Opp'n 53 op. 53 EPA HQ OAR 53 Case Nos. #-# 53 κ 53 RC #.# [002] 53 ERRED BY 53 WITH PREJUDICE 53 ADJUDGED 53 No. CA# 53 Biol Psychiatry 53 #AA [002] 53 #O [002] 53 cmt 53 #J [004] 52 mH 52 See Restatement Second 52 2DR 52 Ann Intern Med 52 MOTION FOR 52 NJSA #A 52 Fitch Rates CWMBS 52 dkt 52 SDW Va. 52 decarboxylase 52 #AP# [003] 52 S1 S# [002] 52 Mtge PT Ctfs Series 52 NE ¼ 52 5 hydroxytryptamine 52 RATING TO 52 OF THE CORPORATIONS 52 hereby GRANTED 52 reh'g denied 52 Psychol Med 52 microRNAs miR 52 Psychopharmacol 52 #B [006] 52 Bankr. ND Ohio 52 RU EEU EUROPE ASIA 52 NJSA #:# [001] 52 Br J Dermatol 52 Model H# 52 SE ¼ 52 constitutively active 52 Ann Rheum Dis 52 # COA R3 52 § #.# [002] 52 J Clin Endocrinol Metab 52 Pub. 52 ADD WATSEKA 52 STATEMENT ON SCHEDULE 52 Neurol 52 Bankr. EDNY 52 AAA/LS1 52 J Nerv Ment Dis 52 Order Granting 52 A.3d 52 WD Tex. 52 RNS Number 52 hereby DENIED 52 #:#-# [006] 52 Red Hat alert RHSA 52 Eur J Cancer 52 EMBO J. 52 NJSA #:# C 52 Y# [004] 52 Assigns Outlooks 52 J Pediatr 52 Torts § 52 #-# SDNY 52 Winnipeg MB R2X 52 Fla. 3d DCA 52 Colo. Sess 52 Schizophr Res 52 Bankr. ND Ill. 52 Slaithwaite CBC 52 Environ Health Perspect 52 doc. 52 Annexin 52 Bankr. 52 L1A 52 Toxicol 52 BANK NATIONAL ASSOCIATION 52 § #-# [001] 52 Apolipoprotein 52 § #.# [004] 52 Psychosom Med 52 alpha GAL 51 Miner Res 51 CrR #.# 51 J Child Adolesc 51 #:#-# [014] 51 ABSpoke 51 #D# [003] 51 #a #a [002] 51 doi #.#/S#-# 51 IT IS HEREBY 51 Bankr. SDNY 51 ABUSED ITS DISCRETION 51 WELLS FARGO BANK 51 Compl. 51 J Affect Disord 51 Bankr. ED Pa. 51 MOTION TO DISMISS 51 Free Full Text 51 #d [002] 51 Phospholipase 51 MRS § 51 2d Dept 51 § #.# b 51 J Natl Cancer Inst 51 Approved Guideline 51 # #-# [006] 51 #-#.# [014] 51 Receptor Antagonists 51 Schematic representation 51 Fla. 2d DCA 51 IIb 51 #G# [002] 51 Crit Care Med 51 Case No. A#A# 51 Psychiatry Clin Neurosci 51 Cyclin 51 suppl. 51 LS Ratings 51 CCL2 51 #.#A [005] 51 Pl. s 51 ,#,# [002] 51 AR3 51 Aaa AAA AAA 51 Ohio Adm.Code #-#-# 51 EMRG VIO 51 Crit Care 51 Heart Circ Physiol 51 § #.# [003] 51 Pathol 51 scavenger receptor 51 AR1 51 § #-#-# [006] 51 Takes Various Actions 51 Arch Gen Psychiatry 51 Br J Cancer 51 Takes Various 51 #:# Distr 51 n.5 51 § #.#.# [002] 51 -# Fed. Cir 51 #C# [010] 51 J Clin 51 #.#-# b [002] 51 Nat Genet 51 #:#-# [037] 51 :6 51 Fed. Cl 51 Supplementary Table 51 Administrative Proceeding File 51 NJAC 6A 51 I# I# [002] 51 Curr Opin 51 USPQ2d 51 MLMI 51 Bankr. ED Va. 51 Highland Addition aka 51 LS4 51 PUBLICATION OF 51 Reductase 50 ANOR 50 Proc Natl Acad Sci 50 #R [004] 50 Infect Dis 50 reh'g 50 UNI XC 50 internal citations omitted 50 mso fareast language 50 Subdivision aka 50 cytoplasmic domain 50 ESTATE OF 50 S# T# R# 50 Anesth 50 #D [003] 50 selective adenosine 50 § #-#.# [001] 50 F# [001] 50 Revs Ser 50 Bankr. WD Mo. 50 J Psychosom Res 50 DC Code § 50 Mol Biol 50 SW ¼ 50 Idaho Code § 50 Eur Heart 50 Clevedon Dons 50 Milnsbridge BC 50 HAS FILED 50 LS5 50 Cancer J Clin 50 FERC Stats 50 § #-#-# [002] 50 n.4 50 :9 50 CanLII 50 ROBBINS LLP 50 Thase ME 50 Exercising jurisdiction 50 #HT [001] 50 Supplementary Appendix 50 § § #-# [001] 50 apolipoproteins 50 aff'd 50 Diabet Med 50 Bankr. SD Fla. 50 SEQUILS 50 OXLEY Open 50 Arch Dermatol 50 B1 MM 50 Fam. Code § 50 ELISA assay 50 1α 50 CHMP Opinion 50 Prudential Ins 50 Bankr. D. Conn. 50 #E# [003] 50 GLc 50 Schizophr Bull 50 USSG § 50 Gastrointest Liver Physiol 50 Bankr. SD Ohio 50 Cal.App 50 Ala. Crim 50 CONSTRUCTION INC. 50 Arch Neurol 50 E2 CLO 50 See USSG 50 FUND INC. 50 Netherton Con B 50 RU EUROPE ASIA EEU 50 Evid 50 USC § #A 50 regulated kinase 50 Ophthalmol 50 p# mitogen activated 50 Peginterferon Alfa 2a 50 Cytochrome P# 50 By AVI SALZMAN 50 induces apoptosis 50 TCA § #-#-# [003] 50 WL # [001] 50 NJSA 2A #A 50 n.1 50 dkt item 50 #,#,# subseries [001] 50 Initiated Phase 50 BACM #-# 50 1ST ADD 50 Bankr. D. Del. 50 Docket Entry No. 50 E# [001] 50 Pediatr 50 1beta 50 Administrator Interpretation 50 CASE NUMBER 50 Sgls 50 Re REMIC 49 dinucleotide 49 U1 OR Book 49 Id. § 49 NCP# NCP# 49 Income Tax Regs 49 Va. Code § 49 Ser #B 49 PHOSPHATE 49 Miss. Ct 49 Sentencing Guidelines Manual 49 Endocrinol 49 Bankr. DNJ 49 Hemplow BC 49 Strk Div 1 49 La.RS #:# [003] 49 § #a [002] 49 Repl 49 apolipoprotein 49 Docket ID 49 Pl. 49 #-#.# [016] 49 DR #-# 49 Clin Cancer 49 P# [004] 49 J Fam Pract 49 MACQUARIE PIB PROJECT 49 § #-#-# [004] 49 p.# [001] 49 #I [003] 49 rev. 49 #.#-# b [001] 49 Receptor Agonist 49 Antiviral Therapy 49 Sgles 49 § #.# d 49 Gynecol Oncol 49 AMENDED 49 State ex rel 49 See id 49 No. #-# Bankr. 49 ESR1 49 Intravascular 49 1alpha 49 Fed.Appx 49 classes #A# #A# 49 n.8 49 § #-# [003] 49 Hirschfeld RM 49 hnRNP 49 certif 49 #d# [001] 49 § #-#.# [003] 49 Sgle Stab Div 49 Brockholes BC 49 :7 49 COOH 49 NJSuper 49 § § #-# [003] 49 Pa.RAP 49 #L [004] 49 DR4 49 EMRG POL 49 Loss Severity LS 49 carboxypeptidase 49 POST CONVICTION RELIEF 49 Ord. 49 DR5 49 Clin Oncol 49 POL PRO 49 #-# Bankr. 49 NM# [003] 49 Med Assoc 49 Ingram Micro SKU 49 J Clin Epidemiol 49 #.#/journal.pmed.# 49 Appellate Rule 49 § #:# [001] 49 Cardiac Troponin 49 Adversary Proceeding 49 J Biol Chem 49 Ph3 OR Book 49 β2 49 Appendix 3B Page 49 Immunol 49 Antitrust Litigation 49 Acid Digestion 49 Transgenic Mice 49 L# L# [002] 49 Synthase 49 RMBS Classes 49 P#S 49 BJ# 49 NJSA #:# [002] 49 Glycoprotein 49 WMUs 2C 2D 2E 49 HE3 49 Pb Cu 49 Vernon Supp 49 Reply Brief 49 n.7 49 internal citation omitted 49 MET VEGFR2 49 affd 49 Nierenberg AA 49 Eur Respir J 49 § #-#-# b [001] 49 n.3 49 contracting activity F# 49 ENVIRONMENTAL PROTECTION AGENCY 49 U# [007] 49 J Appl 49 ISIN XS# affirmed 49 b#x# http:/#.#.#.#/fls.geo/PH #x# #.hyahrtzeit 49 #K [004] 49 #a# [001] 49 Compl 49 See USSG § #B#.# 49 Dual Voltage 49 Intracranial Aneurysms 49 Ohio Adm.Code 49 Certificate Downgraded 49 Int J Geriatr Psychiatry 49 Kidney Int 49 Otolaryngol Head Neck Surg 49 Arch Pediatr Adolesc Med 49 Sgle Strk Div 49 #C# [003] 49 surfactant protein 49 Ptf 49 MC# [001] 49 CA# [003] 49 Psychopharmacol Bull 49 SPECIFICATIONS 49 bispecific 49 Cleator MC 49 S#C [002] 49 3d [002] 49 Toronto Symbole au 49 Defs. 49 Legal #.# 49 internal quotations omitted 49 Bankruptcy Procedure 49 #A #A [002] 49 C# C# [003] 49 Ser #A 49 § #B#.# [002] 49 § #-#.# [002] 49 Histologic 49 SENIOR LEAGUE DIVISION 49 #.# subd [004] 48 PETITION FOR 48 ALARM W 48 Hallux 48 ll.# 48 mediated apoptosis 48 selective inhibitor 48 #:#-# [019] 48 ORDERED ADJUDGED AND DECREED 48 :3 48 SH2 domain 48 Acta Psychiatr Scand 48 P# [002] 48 #a# [002] 48 TC Memo 48 ESMO Accepted Abstract 48 Mol Psychiatry 48 lipoxygenase 48 cAMP dependent 48 USC § § #e 48 Oncol 48 J Clin Psychopharmacol 48 IDR Affirmed 48 CA# [004] 48 ARS § 48 § #A [001] 48 MIL DTL 48 Psychiatry Res 48 Bruton tyrosine kinase 48 C'ship Sgles 48 Mthly Medal 48 J Psychiatr Res 48 :1 48 Seq 48 PMID # [002] 48 OBJECTION TO 48 HQ H# 48 Therasense 48 Sup. Ct 48 mediated inhibition 48 Inj 48 Polymorphism 48 Oropharyngeal 48 integrin alpha 48 #CV# 48 Notes CUSIP Nos. 48 Resp 48 Compl. ¶ 48 WF2 48 Catenin 48 Arch Dis Child 48 Sgle Stab Medley 48 Butterfly Valve 48 interlocutory judgment 48 Int Clin Psychopharmacol 48 1LB 48 #A #A [001] 48 Mortgage PT Ctfs 48 By TERESA RIVAS 48 pL 48 #.#-# [006] 48 #.#A [004] 48 NJSA #:#-# [004] 48 Urol 48 Plaintiffs Appellees 48 #Y# [001] 48 #-#.# [017] 48 Soc Sci Med 48 #J [002] 48 :4 48 Pa.Super 48 WAS CONTACTED 48 Structured Asset 48 Gde G 48 subseries 48 CV# [003] 48 Bnds 48 3d Ex 48 #B.# [002] 48 Eur J Neurol 48 S# [005] 48 C.# 48 Liposomal 48 WL # 2d Cir 48 Swedenburg v. Kelly 48 nonfinal 48 Jury Instructions 48 substrate specificity 48 #-#-# [026] 48 Agilent #B [002] 48 Double Blind Placebo 48 COMPANIES ACT 48 Q#A 48 CFR § #.# [004] 48 Pocock SJ 48 Muni Debt 48 #A# [008] 48 T#N R#E 48 E# [005] 48 AAA Watch Neg 48 Rehabil 48 Complaint ¶ 48 receptor CD# 48 Notes CUSIP 48 Special Servicer Rating 48 So.3d 48 :# [002] 48 RFMSI 48 Jury Instruction 48 footnotes omitted 48 sua sponte dismissal 48 Int J Epidemiol 48 ribosomal protein 48 Hanney Utd 48 plasminogen activator inhibitor 48 DEED OF TRUST DATED 48 B# [004] 48 sub nom 48 dimeglumine 48 Gly 48 nonsuit 48 eosin 48 P2X 48 internal quotation omitted 48 extracellular signal 48 Psychiatr 48 T8N 48 Section #-#-# [006] 48 OSLER 48 Ann Surg 48 PROJECTS FOR 48 eukaryotic initiation factor 48 Docket Entry 48 HOUSE Remains 48 transferase 48 Variable Interest Entities FIN 48 #-# Ala. Civ 48 Emerg Care 48 #/Aug 48 Loss Severity 48 IN SHARES 48 COMPLETES ACQUISITION OF 48 n.9 48 0D 48 #.#-# Equal Opportunity 48 INTERACTIVE ENTERTAINMENT 48 Decl 48 REVERSED 48 #-#-# [068] 48 AA Watch Neg 48 Fitch Ratings Affirms 48 WB #-#/# #-#/# 48 Neurosci 48 Golcar Lib B 48 #A# [005] 47 USLW 47 Tranches 47 Polymerase 47 ARS § #-#.# 47 Gunderson JG 47 Oral Argument 47 v OHIM 47 Phosphodiesterase 47 n.6 47 Amended Judgment 47 #A [002] 47 Rfdg Revs 47 succinate dehydrogenase 47 Hall BF Poster 47 #:# -# [001] 47 REMAND 47 GULF WAR 47 mso bidi language 47 ARS § #-# [001] 47 DU# [002] 47 7R 47 QVC Item 47 B Sgles 47 #-# [031] 47 Diabetic Nephropathy 47 Retinal Camera 47 RIGHTS ISSUE 47 E# E# [002] 47 Cell Biol 47 USC § #a [001] 47 assigns Loss Severity 47 L# B# [002] 47 NOTICE OF 47 PAM# [001] 47 Sgle 47 Neurobiol 47 NATIONAL CIRCUIT FORREST 47 Am J Pathol 47 mRNA encoding 47 DEV DA TOMAR NEXT 47 Avago ACPL 47 Stab Div 1 47 WBCMT 47 Isomer 47 Kannel WB 47 HONDA ACCORD 47 Sagittal 47 Hr'g 47 monocytes macrophages 47 Holiday Trustee L# 47 See INA § 47 CITATION 47 interferon γ 47 Am J Gastroenterol 47 Meltzer HY 47 Linthwaite Hall 47 Golcar Lib 47 EXPLANATORY MEMORANDUM 47 OP# [002] 47 Receptor Antagonist 47 UNDIVIDED INTEREST 47 F3d 47 Easington Spts 47 acetylcholine receptor 47 Black Ink Cartridge 47 AAA/F1 + 47 F# [003] 47 beta tubulin 47 niacin vitamin 47 #Ga 47 transmembrane protein 47 Bacteremia 47 #-# [009] 47 Brockholes B 47 CYP #D# 47 phosphorothioate 47 Rheumatol 47 WpHG mit dem Ziel 47 Cell Mol Biol 47 GOs AA 47 #B.# [003] 47 EM1 47 ASHGROVE Open 47 Nos. #-# [001] 47 #N [006] 47 Appellant asserts 47 CFR § #.# [003] 47 TRUS 47 #:# [013] 47 CUSIP Number 47 #N# [006] 47 Confocal 47 L4 B# 47 § #:# [002] 47 Str Div 1 47 PROSPECTUS 47 #-# [027] 47 PT# [002] 47 xenograft model 47 USC § #a b 47 oligomer 47 CONVERSION OF 47 section #.#.# 47 Disord 47 FORD FUSION 47 DCENT 47 BRIEF Moody asgns 47 #.# [042] 47 Monoamine Oxidase 47 § #.# [006] 47 Accelerated Approval 47 downstream effector 47 #.# subd [006] 47 -Cúper 47 Certifications Commercial Items 47 N methyl 47 EM BS 47 #HT [003] 47 Tapo Canyon Rd 47 cytotoxic conjugate 47 Vets Sgles 47 XIENCE TM 47 #E [005] 47 #A #A [003] 47 postjudgment 47 Portishead WMC 47 Pressure Transducer 47 Genes Dev 47 CDO #-# Ltd. 47 Novel Inhibitor 47 LUPA 47 Mol Med 47 B# B# B# B# 47 Port Auth 47 PR SER 47 ASME Boiler 47 A2 A3 47 Marsh Lib 47 B Raja Rajkrishna 47 Sports Exerc 47 #.#-# [005] 47 DO NOT EMAIL 47 Crosland Moor Con 47 Marsh Utd 47 § #-#-# b [002] 47 ß2 47 Int J Cancer 47 Trapeza CDO 47 B2 B3 47 S#A [001] 47 #J# [004] 47 Clin Endocrinol 47 AZ# [002] 47 syntaxin 47 #D #D [002] 47 Histone 47 Struct 47 gene polymorphism 47 RETIREMENT PLAN 47 Geriatr 47 defendants appellees 47 Rating Amount mil. 47 su# 47 Resecuritization 47 § #.#.# [001] 47 myc 47 CA GOs 47 Subparagraph 47 S# S# [003] 47 NJSA 2C :5 47 OCGA § #-#-# [007] 47 Def. 47 mem. op 47 Loch Lomond Addition 47 CT Tremlett 47 NJSA 2C :2 47 pp. #-# fn 47 5th DCA 47 Ann Emerg Med 47 IFS Rating 47 Rfdg Bonds 47 Doc. # 47 function var = 47 Clin Infect Dis 47 #P# [004] 47 BEETHOVEN Symphony No. 47 de bons de 47 RENASYS TM 47 Lenalidomide 47 Civ.R. 47 SDNY 47 Prof. Code § 47 AT# [004] 47 No. B# 47 subpart 47 La.RS 47 MINING COMPANY 47 Annu Rev 47 appellants contend 46 Topoisomerase 46 OCGA § #-#-# [002] 46 TRANSACTION WITH 46 MAILED 46 #p# [003] 46 Sitrans 46 FCC Rcd # 46 Assigns LS 46 R#E 46 Orally Active 46 USC § #u 46 CSA C#.# 46 CFR #.#b 46 Workington Jnrs 46 coactivator 46 Endovascular System 46 Wpg R2X #B# 46 Small Molecule Inhibitors 46 Chp 46 ¼ l 46 dated #-#-# [001] 46 Tex. App 46 HOLE NO 46 TIMP 1 46 Thoracic Endoprosthesis 46 V# P# [001] 46 Phosphorylation 46 § #A.# 46 replicon 46 #PD 46 #:# -# [004] 46 Lockwood Con 46 2Z 46 Protease Inhibitor 46 PLEASE SEE 46 ERK1 2 46 #AB [002] 46 N# [005] 46 PHASE III 46 HLA DRB1 * 46 SETTLEMENT OF 46 Holes WAT# 46 VGS = 46 RSY 46 v Eynsham 46 FUSILEV TM 46 #A #B [002] 46 :2 46 LOCAL LAW 46 Third Amended Complaint 46 Sgle Strk 46 quoting Restatement Second 46 Cleckheaton Spts 46 Appellants argue 46 GAILES Sgle Stab Div 46 Markman Hearing 46 FR Doc 46 #L# [001] 46 Physiol 46 RATING ON 46 Steventon Res 46 austriamicrosystems Introduces 46 Publ 46 CAM1 46 B Sgles Final 46 # PBTD # 46 Proc Am 46 S7 S# 46 JM et al 46 S Nikkor #mm 46 NOTICE OF TRUSTEE 'S 46 Alkyl 46 Hennekens CH 46 #A #B #C 46 p# p# 46 Stats. 46 remittitur 46 #C# [007] 46 Patrik Sandell Skoda Fabia 46 General Psychiatry #:#-#,# 46 Grove Rgrs 46 Malmesbury Vic 46 SR NYSEArca 46 drlg 46 STRATEGIC PLAN 46 Hematol 46 HemosIL 46 spud #-#-# drlg [003] 46 WIDTH = 46 Pharmacother 46 IRCP 46 KSP inhibitor 46 BG# [001] 46 CAPITAL INC. 46 Sikes Addition 46 transgenic mice expressing 46 Rev Bds 46 BAW Mendis 46 o -Dynamic Messenger